Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: A 12-month, randomized, double-blind study

Clinical Therapeutics

Volumn 26, Issue 8, 2004, Pages 1228-1236

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   Bertone, Gianandrea ^a   Piccinni, Mario N ^a   Fogari, Elena ^a   Ciccarelli, Leonardina ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

glucose metabolism; hypertension; lipid profile; nifedipine GITS; telmisartan; type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CHOLESTEROL; DIURETIC AGENT; DOXAZOSIN; FLUINDOSTATIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; METOPROLOL; NIFEDIPINE; PRAVASTATIN; REPAGLINIDE; SIMVASTATIN; SULFONYLUREA; TELMISARTAN; UNINDEXED DRUG; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; BORDERLINE HYPERTENSION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEADACHE; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG COMBINATION; HYPERTENSION; MIDDLE AGED;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; NIFEDIPINE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 6344261602     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)80049-3     Document Type: Article

References (41)

1. Beckman JA, Creager MA, and Libby P Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management JAMA 287 2002 2570 2581
2. American Diabetes Association Clinical practice recommendations 2002 Diabetes Care 25 Suppl 1 2002 S1 S147
3. Derosa G, Cicero AF, Ciccarelli L, and Fogari R A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus Clin Ther 25 2003 2006 2021
4. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
5. Kasiske BL, Ma JZ, Kalil RS, and Louis TA Effects of anti-hypertensive therapy on serum lipids Ann Intern Med 122 1995 133 141
6. Ames RP A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides Am J Cardiol 77 1996 12b 16b
7. Schmitz G, Stumpe KO, Herrmann W, and Weidinger G Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial Blood Press 5 1996 354 359
8. Krone W, and Nagele H Effects of antihypertensives on plasma lipids and lipoprotein metabolism Am Heart J 116 1988 1729 1734
9. 1 blockers in the treatment of hypertension and syndrome X Can J Cardiol 16 Suppl E 2000 41E 44E
10. Sowers JR, and Epstein M Diabetes mellitus and hypertension: Emerging therapeutic perspectives Cardiovasc Drug Rev 13 1995 149 210
11. Lee AF, and Struthers AD The impact of angiotensin converting enzyme inhibitors on the arterial wall Vasc Med 1 1996 109 113
12. Weber MA Comparison of type I angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension J Hypertens Suppl 15 1997 531 536
13. Hernandez-Hernandez R, Sosa-Canache B, and Velasco M Angiotensin II receptor antagonists role in arterial hypertension J Hum Hypertens 16 Suppl 1 2002 S93 S99
14. Pylypchuk GB ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema Ann Pharmacother 32 1998 1060 1066
15. Lerch M, Teuscher AU, and Beissner P Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents J Cardiovasc Pharmacol 31 1998 576 580
16. Appel GB, Radhakrishnan J, Avram MM for the RENAAL Study Group Analysis of metabolic parameters as predictors of risk in the RENAAL study Diabetes Care 26 2003 1402 1407
17. Cheung R, Lewanczuk RZ, and Rodger NW The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy Int J Clin Pract 53 1999 584 592
18. Derosa G, Cicero AF, and Mugellini A Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients J Hum Hypertens 17 2003 433 435
19. Wienen W, Entzeroth M, and van Meel JC A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist Cardiovasc Drug Rev 18 2000 127 156
20. Sharpe M, Jarvis B, and Goa KL Telmisartan: A review of its use in hypertension Drugs 61 2001 1501 1529
21. Masuo K, Mikami H, Ogihara T, and Tuck ML Metabolic effects of long-term treatments with nifedipine-retard and captopril in young hypertensive patients Am J Hypertens 10 1997 600 610
22. Terpstra WE, May JF, and Smit AJ Effects of nifedipine on carotid and femoral arterial wall thickness in previously untreated hypertensive patients Blood Press Suppl Suppl 1 2003 22 29
23. Mancia G, Brown M, Castaigne A for the INSIGHT Study Group Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT) Hypertension 41 2003 431 436
24. Screening for diabetes Diabetes Care 24 Suppl 1 2001 S21 S24
25. Guidelines Subcommittee 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension J Hypertens 17 1999 151 183
26. Mogensen CE, Keane WE, and Bennett PH Prevention of diabetic renal disease with special reference to microalbuminuria Lancet 346 1995 1080 1084
27. European Diabetes Policy Group 1999 A desktop guide to type 2 diabetes mellitus Diabetic Med 16 1999 716 730
28. Heding LG Determination of total serum insulin (IRI) in insulin-treated diabetic patients Diabetologia 8 1972 260 266
29. Bunn HF, Gabbay KH, and Gallop PM The glycosylation of hemoglobin: Relevance to diabetes mellitus Science 200 1978 21 27
30. [author's translation] Borner K, and Klose S Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA II) J Clin Chem Clin Biochem 15 1978 121 130
31. Wahlefeld AW Triglycerides determination after enzymatic hydrolysis Bermeyer HU Methods of Enzymatic Analysis 2nd ed. 1974 Academic Press Gaithersburg, Md 18 31
32. Havel RJ, Eder HA, and Bragdon JH The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J Clin Invest 34 1955 1345 1353
33. Friedewald WT, Levy RI, and Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge Clin Chem 18 1972 499 502
34. Matthews DR, Hosker JP, and Rudenski AS Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
35. Bemobich E, de Angelis L, Lerin C, and Bellini G The role of the angiotensin system in cardiac glucose homeostasis: Therapeutic implications Drugs 62 2002 1295 1314
36. Moan A, Hoieggen A, and Seljeflot I The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity J Hypertens 14 1996 1093 1097
37. Trenkwalder P, Lehtovirta M, and Dahl K Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes J Hum Hypertens 11 Suppl 2 1997 581 583
38. Rippin J, Bain SC, Barnett AH for the DETAIL Study Group Rationale and design of Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study J Diabetes Complications 16 2002 195 200
39. Sharma AM, Janke J, and Gorzelniak K Angiotensin blockade prevents type 2 diabetes by formation of fat cells Hypertension 40 2002 609 611
40. Asmar R Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus J Renin Angiotensin Aldosterone Syst 2 Suppl 2 2001 S8 S11
41. Weber MA The 24-hour blood pressure pattern: Does it have implications for morbidity and mortality? Am J Cardiol 89 2002 27A 33A